8-K: TScan Therapeutics Announces $150 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

TScan Therapeutics has priced an upsized public offering of common stock and pre-funded warrants, expected to generate gross proceeds of approximately $150.1 million.

Summary

• TScan Therapeutics has announced the pricing of a public offering of 2,472,581 shares of common stock at $7.13 per share.
• The company is also offering pre-funded warrants to purchase up to 18,577,419 shares of common stock at $7.1299 per warrant, with an exercise price of $0.0001 per share.
• The gross proceeds from the offering are expected to be approximately $150.1 million, before deducting underwriting discounts and commissions and other offering expenses.
• The underwriters have a 30-day option to purchase up to an additional 3,157,500 shares of common stock.
• The offering is expected to close on or about April 19, 2024, subject to customary closing conditions.
• TScan intends to use the net proceeds from the offering for general corporate purposes.
• The company expects its existing cash, cash equivalents, and marketable securities, combined with the proceeds from this offering, to fund operations into the fourth quarter of 2026.
• As of March 31, 2024, the company had cash, cash equivalents, and marketable securities of $162.8 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company has successfully upsized its offering, indicating investor interest, and secured funding into late 2026. However, the reliance on assumptions and the potential for earlier capital depletion temper the overall positive outlook.

Positives

• The upsized offering is expected to provide TScan with significant capital, approximately $150.1 million in gross proceeds.
• The company expects to fund operations into the fourth quarter of 2026, providing a runway for development.
• The offering includes an underwriter option for additional shares, which could further increase the capital raised.
• The company has a solid cash position of $162.8 million as of March 31, 2024, prior to the offering.

Negatives

• The company will receive nominal proceeds, if any, from the exercise of the pre-funded warrants.
• The company's estimate of funding into the fourth quarter of 2026 is based on assumptions that may prove to be wrong.
• The company could use its available capital resources sooner than it currently expects.

Risks

• The offering is subject to market, regulatory, and other conditions, and there is no guarantee it will be completed.
• The company's estimate of funding into the fourth quarter of 2026 is based on assumptions that may prove to be wrong.
• The company could use its available capital resources sooner than it currently expects.
• The company's actual financial results for the three months ended March 31, 2024, could be materially different from the preliminary information provided.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities, combined with the proceeds from this offering, to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2026.

Management Comments

• The company intends to use the net proceeds from the offering for general corporate purposes.

Industry Context

This offering reflects the ongoing need for capital in the biopharmaceutical industry, particularly for companies in the clinical stage of development. The funds raised will support TScan's research and development efforts in TCR-T therapies for cancer.

Comparison to Industry Standards

• The offering size of $150 million is a significant capital raise for a clinical-stage biopharmaceutical company, which is comparable to other companies in the sector seeking to fund clinical trials and research.
• The use of pre-funded warrants is a common mechanism for companies to raise capital while providing flexibility to investors.
• The expected funding runway into the fourth quarter of 2026 is a typical timeframe for companies in this stage of development, allowing for continued progress in clinical programs.
• Comparable companies that have recently raised capital include Xilio Therapeutics, which raised $125 million in a public offering, and Caribou Biosciences, which raised $150 million in a private placement.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company's employees will benefit from the increased financial stability and runway for development.
• Customers and partners may see increased confidence in the company's ability to execute its plans.
• Creditors may view the company as a lower credit risk due to the increased cash position.

Next Steps

• The offering is expected to close on or about April 19, 2024, subject to customary closing conditions.
• The company will use the net proceeds from the offering for general corporate purposes.

Key Dates

Keywords

public offering, common stock, pre-funded warrants, TScan Therapeutics, capital raise, biopharmaceutical, TCR-T, cancer therapy, underwriting, financing